INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Fulgent Genetics, Inc. (NASDAQ: FLGT) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Company Overview - Fulgent Genetics, Inc. is a biotechnology company that specializes in diagnostic and genetic laboratory testing services and develops pharmaceutical treatments for various diseases and medical conditions [3] Allegations and Investigations - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Fulgent, stemming from allegations of providing potentially misleading business information to investors [1] - On February 28, 2025, Fulgent disclosed in its annual report that it received a civil investigative demand from the U.S. Department of Justice related to potential false claims submitted under the federal COVID-19 testing program for uninsured individuals [4] Market Reaction - Following the disclosure of the civil investigative demand, Fulgent's stock price declined by $0.41 per share, or approximately 2.61%, closing at $15.28 per share on March 3, 2025 [5]